Kelly, Patrick

A phase 2 study of IPI-926, an oral hedgehog inhibitor, in patients with myelofibrosis.

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 7111-7111

10.1200/jco.2014.32.15_suppl.7111